RESEARCH ARTICLE
Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis Xue Zheng1, Zhi Zhan2, Duolan Naren1, Jing Li3, Tianyou Yan1, Yuping Gong1*
a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
OPEN ACCESS Citation: Zheng X, Zhan Z, Naren D, Li J, Yan T, Gong Y (2017) Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis. PLoS ONE 12(9): e0185053. https://doi.org/10.1371/journal. pone.0185053
1 Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China, 2 Department of Cardiology, Zhong Shan Hospital, Fu Dan University, Shanghai, China, 3 Department of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China *
[email protected]
Abstract Background The recent application of gene-sequencing technology has identified many new somatic mutations in patients with myelodysplastic syndromes (MDS). Among them, serine and arginine rich splicing factor 2 (SRSF2) mutations belonging to the RNA splicing pathway were of interest. Many studies have already reported the potential prognostic value of SRSF2 mutations in MDS patients, with controversial results. Therefore, a meta-analysis was performed to investigate their prognostic impact on MDS.
Editor: Robert K Hills, Cardiff University, UNITED KINGDOM Received: April 19, 2017
Methods
Accepted: September 6, 2017
Databases, including PubMed, Embase and the Cochrane Library, were searched for relevant studies published up to 14 October 2016. Overall survival (OS) was selected as the primary endpoint, and acute myeloid leukemia (AML) transformation was the secondary endpoint. We extracted the corresponding hazard ratios (HRs) and their 95% confidence intervals (CIs) for OS and AML transformation from multivariate Cox proportional hazards models. The combined HRs with their 95% CIs were calculated using fixed or random effect models.
Published: September 27, 2017 Copyright: © 2017 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files.
Results
Funding: The work was supported by the Foundation of the Science & Technology Department of Sichuan Province (No. 2015SZ0234-5), Foundation of Administration of traditional Chinese medicine of Sichuan Province (No. 2014A038) and the Foundation of Science and Technology Bureau of Chengdu (No. 2016-HM0100001-SF), http://www.scst.gov.cn/. YPG received
A total of 10 cohort studies, covering 1864 patients with de novo MDS and 294 patients with SRSF2 mutations, were included in the final meta-analysis. Our results indicated that SRSF2 mutations had an adverse prognostic impact on OS (p
